Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase)
Min-Taek Lee, Ju Won Lee, Hyeon Ji Lee, Jong-Min Lee, Jae Chol Choi, Kang-Mo Gu, Sun-Young Jung · 2023
Read Interstitial lung disease following COVID-19 vaccination: a disproportionality analysis using the Global Scale Pharmacovigilance Database (VigiBase) by Min-Taek Lee, Ju Won Lee, Hyeon Ji Lee, Jong-Min Lee, Jae Chol Choi, Kang-Mo Gu, Sun-Young Jung (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10729117.txt.
Description
Min-Taek Lee and co-authors check safety reports for a lung signal after COVID vaccination, in a 2023 study. Case reports had raised the question of interstitial lung disease following the shots, but no population-scale study existed. The team mined the VigiBase database of side effects, covering the first two years of the rollout, and compared reporting rates for COVID vaccines against all other vaccines.
Of about 1.2 million vaccine-related reports, six hundred and seventy-nine concerned the disease. Most involved the leading messenger RNA vaccine, then a viral vector one, then the second RNA vaccine. The odds for COVID vaccines came out slightly below one, meaning no excess signal, and the same held against influenza vaccines, known to cause the condition. The authors say results can inform later vaccination strategy for lung patients, while asking for larger prospective studies.
Catalog record
| CREATOR | Min-Taek Lee, Ju Won Lee, Hyeon Ji Lee, Jong-Min Lee, Jae Chol Choi, Kang-Mo Gu, Sun-Young Jung |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |